VesiVax-adjuvanted vaccine cocktail against gonorrhea
Official title: Project 1 - VesiVax®-adjuvanted cocktail vaccine formulation against Neisseria gonorrhoeae (CIIG)
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-11394897 · Data updated 2026-11-12
A vaccine candidate using a novel adjuvanted vaccine formulation aims to prevent gonorrhea, targeting a highly antibiotic-resistant N. gonorrhoeae infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | August 12, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $614,068 |
| NIH project number | 5U19AI189178-02 |
| Project ID | NIH-11394897 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk of gonorrhea or populations with high exposure who may participate in future clinical vaccine development.
✕Less likely to help
People who are not candidates for vaccination or who are not at risk for gonorrhea may not benefit.
What this research studies
This project aims to advance a vaccine designed to prevent gonorrhea by combining a genetically modified Neisseria meningitidis outer membrane vesicle with synergetic gonorrhea antigens and a powerful adjuvant. The approach uses the VesiVax liposome platform to deliver these components in a way that could generate durable, broad protection across diverse strains. The work focuses on moving vaccine candidates toward clinical development, addressing antigenic diversity and lack of natural immunity. If successful, this could lead to a new preventive option for individuals at risk of gonorrhea.
Why it matters
Potential benefit: If successful, the vaccine could reduce gonorrhea incidence and help curb antibiotic resistance by preventing infections.
How similar studies have gone: Prior data from MenB OMV vaccines suggest some protective signals against gonorrhea, but broad, durable protection remains unproven.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Fujii, Gary — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Fujii, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.